All In MedTech

Device Trial Radar · NCT04011722

Portico Next Generation Approval Study

Evaluation of the Portico™ NG (Next Generation) Transcatheter Aortic Valve in High and Extreme Risk Patients With Symptomatic Severe Aortic Stenosis

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

333

Actual

Start

Sep 17, 2019

Primary completion

Jan 12, 2023

Study completion Jan 2033

Sponsor

Lead sponsor
Abbott Medical DevicesPublic (ABT)
Sponsor type
Industry
First posted
Jul 8, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to evaluate the acute safety and effectiveness of the next-generation Navitor (Portico™ NG) Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30 days in a high or extreme surgical risk patient population to support CE (Conformité Européenne) Mark and FDA approval.

Conditions

  • Symptomatic Severe Aortic Stenosis

Interventions

  • Portico™ NG (Navitor) Valve and FlexNav™ Delivery SystemDevice

    Subjects will undergo transcatheter aortic valve implantation (TAVI) with the new generation Portico NG (Navitor) valve and second-generation FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.

  • Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery SystemDevice

    Subjects will undergo transcatheter aortic valve implantation (TAVI) with the Navitor Titan valve and large FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Safety Endpoint is All-cause MortalityTime frame: at 30 days
  2. Primary Effectiveness Endpoint is Moderate or Greater Paravalvular LeakTime frame: at 30 days

Locations

28 sites in 5 countries. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Los Robles Regional Medical Center

    Thousand Oaks, California

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia

25 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.